Ind Swift Laboratories
91.90
-0.98(-1.06%)
Market Cap₹675.34 Cr
PE Ratio3.24
IndustryHealthcare
Company Performance:
1D-1.06%
1M-3.99%
6M-15.88%
1Y-14.11%
5Y+50.29%
View Company Insightsright
More news about Ind Swift Laboratories
12Sept 25
IND-SWIFT LABORATORIES Ventures into Cricket with 50:50 Joint Venture for Chandigarh Premier League
Ind Swift Laboratories approves a 50:50 joint venture to participate in the inaugural Chandigarh Premier League (CPL). The company will invest up to Rs. 2.00 crores in this Limited Liability Partnership with Mr. Nikhil Goel. The venture aims to sponsor/own a cricket team in the CPL and engage in other sports-related initiatives. This strategic move is driven by cricket's commercial potential in India and the opportunity to establish an early presence in the CPL.
28Aug 25
Ind-Swift Laboratories Promoters Acquire 39.46 Lakh Shares Through Amalgamation Scheme
Ind Swift Laboratories' promoter group acquired 39,46,094 equity shares through an amalgamation scheme approved by the National Company Law Tribunal. Essix Biosciences Limited led the acquisition with 25,55,014 shares. The company's equity share capital increased from INR 73.49 crore to INR 81.61 crore, with total shares rising to 8,16,11,558. This move significantly increased the promoters' stake in the company, with Essix Biosciences now holding 34.04% of total share capital.
13Aug 25
Ind-Swift Lab Reports Q1 EBITDA Turnaround, Revenue Growth Amid Profit Decline
Ind Swift Laboratories Limited reported mixed Q1 financial results. The company achieved an EBITDA turnaround, posting ₹36.00 million compared to a ₹65.00 million loss in the previous year, with an EBITDA margin of 2.36%. Revenue grew by 4.08% to ₹1.53 billion. However, consolidated net profit declined by 69.86% to ₹88.00 million from ₹292.00 million in the same quarter last year. The board approved these unaudited results in a meeting on August 13.
11Aug 25
Ind Swift Laboratories Reports Strong Profit Growth and Completes Merger with Ind Swift Limited
Ind Swift Laboratories Limited (ISLL) announced robust financial results following its merger with Ind Swift Limited. The company reported a standalone net profit of Rs. 256.09 crores and revenue from operations of Rs. 549.65 crores. The merger, approved by NCLT, became effective on August 8. ISLL allotted 14.20 lakh preference shares to former Ind Swift Limited shareholders and converted 15.32 lakh equity warrants. Strategic asset sales and exceptional items contributed Rs. 223.20 crores to profits. The company's standalone EPS stood at Rs. 38.08.
31Jul 25
Ind-Swift Laboratories Merger with Ind-Swift Limited Gets NCLT Approval, Effective August 8, 2025
The National Company Law Tribunal (NCLT) has approved the merger of Ind-Swift Limited with Ind-Swift Laboratories Limited (ISLL). The amalgamation will be effective from August 8, 2025, with March 31, 2024, as the appointed date. The record date for determining eligible shareholders is set for August 14, 2025. Post-merger, ISLL's authorized share capital will increase to Rs. 140.00 crores, comprising 11.50 crore equity shares and 25.00 lakh preference shares. Ind-Swift Limited will be dissolved without winding up. The merger is expected to create operational synergies and potentially strengthen the market position of the combined entity.
28Jul 25
Ind-Swift Laboratories Secures NCLT Approval for Merger with Ind-Swift Limited
Ind Swift Laboratories Limited (ISLL) has obtained final approval from the National Company Law Tribunal (NCLT) for its merger with Ind-Swift Limited. The NCLT Chandigarh Bench approved the amalgamation scheme, which will affect shareholders and creditors of both companies. ISLL has made the NCLT order publicly available on its website for transparency. The merger is expected to streamline operations and create potential synergies between the two entities.
18Jun 25
Ind-Swift Laboratories Invests ₹950 Million in Khandelwal Finance's OCRPS
Ind-Swift Laboratories has approved an investment of ₹950.00 million in Khandelwal Finance through Optionally Convertible Redeemable Preference Shares (OCRPS). This strategic move represents a significant financial decision for the pharmaceutical company, potentially diversifying its investment portfolio and providing opportunities for future equity conversion or steady income through fixed dividends.
28Mar 25
Ind-Swift Laboratories Approves Rs 20 Crore Short-Term Advance to Ashok Investors Trust
Ind-Swift Laboratories Ltd (ISLL) has approved a short-term advance of up to Rs 20 crore to Ashok Investors Trust Limited (AITL), a registered NBFC. The advance is in the form of an Inter-Corporate Deposit with a 30-day term, extendable for another 30 days, at 10% annual interest. The transaction is secured by post-dated cheques and is not a related party transaction. ISLL already holds 800 NCDs of AITL, each with a face value of Rs 5,00,000.
Ind Swift Laboratories
91.90
-0.98
(-1.06%)
1 Year Returns:-14.11%
Industry Peers
Sun Pharmaceutical
1,737.00
(-1.08%)
Divis Laboratories
6,496.50
(+0.31%)
Torrent Pharmaceuticals
3,834.30
(+0.37%)
Cipla
1,496.30
(-0.29%)
Dr Reddys Laboratories
1,265.80
(-1.38%)
Lupin
2,107.00
(-0.31%)
Zydus Life Science
917.80
(-1.08%)
Mankind Pharma
2,193.30
(-1.63%)
Aurobindo Pharma
1,211.40
(-0.54%)
Alkem Laboratories
5,566.00
(-0.55%)